Search research articles
Contact Us
Filters
Showing results (111-120 of 212) with videos related to
Page
of 22
Sort By:
Annals of Hematology
|
December 1, 2017
Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation
Andrew T Kuykendall, Savan Shah, Chetasi Talati, et al.
Critical Reviews in Oncology/Hematology
|
May 11, 2010
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes
John F Seymour, Pierre Fenaux, Lewis R Silverman, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 19, 2009
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening
Róbert Kiss, Tímea Polgár, Annet Kirabo, et al.
Leukemia
|
July 31, 2020
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)
Seongseok Yun, Susan M Geyer, Rami S Komrokji, et al.
Leukemia Research
|
June 15, 2007
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia
Francis J Giles, Alan F List, Michael Carroll, et al.
Leukemia Research
|
May 3, 2015
Impact of tobacco usage on disease outcome in myelodysplastic syndromes
Asmita Mishra, Dana E Rollison, Thomas H Brandon, et al.
Leukemia Research
|
April 29, 2019
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)
David A Sallman, Rami S Komrokji, Kendra L Sweet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 17, 2019
Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks
Sriram Sundaravel, Wen-Liang Kuo, Jong Jin Jeong, et al.
Acta Haematologica
|
November 22, 2014
A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution
Deniz Peker, Eric Padron, John M Bennett, et al.
American Journal of Hematology
|
April 23, 2013
Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
Asmita Mishra, Maria Corrales-Yepez, Najla Al Ali, et al.
Page
of 22
Search research articles
Search
Showing results (111-120 of 212) with videos related to
Sort By:
Page
of 22
Annals of Hematology
|
December 1, 2017
Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation
Andrew T Kuykendall, Savan Shah, Chetasi Talati, et al.
Critical Reviews in Oncology/Hematology
|
May 11, 2010
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes
John F Seymour, Pierre Fenaux, Lewis R Silverman, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 19, 2009
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening
Róbert Kiss, Tímea Polgár, Annet Kirabo, et al.
Leukemia
|
July 31, 2020
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)
Seongseok Yun, Susan M Geyer, Rami S Komrokji, et al.
Leukemia Research
|
June 15, 2007
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia
Francis J Giles, Alan F List, Michael Carroll, et al.
Leukemia Research
|
May 3, 2015
Impact of tobacco usage on disease outcome in myelodysplastic syndromes
Asmita Mishra, Dana E Rollison, Thomas H Brandon, et al.
Leukemia Research
|
April 29, 2019
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)
David A Sallman, Rami S Komrokji, Kendra L Sweet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 17, 2019
Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks
Sriram Sundaravel, Wen-Liang Kuo, Jong Jin Jeong, et al.
Acta Haematologica
|
November 22, 2014
A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution
Deniz Peker, Eric Padron, John M Bennett, et al.
American Journal of Hematology
|
April 23, 2013
Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
Asmita Mishra, Maria Corrales-Yepez, Najla Al Ali, et al.
Page
of 22